Genovis is reorganizing and closing its subsidiary GeccoDots


For the Group, the reorganization will entail cost and capital expenditure
savings of approximately SEK 6 million over a 12-month period. All intangible
and tangible assets have been transferred to the Parent Company, which decided
to sell the intellectual property rights behind the Nanomotus project to the
inventors against future royalties.
To date, Genovis has focused solely on customers who work with antibodies, but
will now focus fully on the enzyme market and this fall will launch the first
products aimed at all customers working in protein characterization.

“For the Group and everyone who works at Genovis it is extremely important to
have a clear focus and dedicate all resources to the enzyme business. Both
existing and new enzyme products will contribute to continued increased sales
and help Genovis to achieve a positive cash flow,” says Fredrik Olsson, CEO of
Genovis.
For more information, please contact: Fredrik Olsson, CEO, Genovis AB Tel: 0046
(0)46 -101233 fredrik.olsson@genovis.com (sarah.fredriksson@genovis.com)
ABOUT GENOVIS

Genovis’ business concept is to offer customers in the pharmaceutical and
medical device industries tools that facilitate and save time in the development
of new treatment methods and diagnostics. Today Genovis sells several enzyme
products known as SmartEnzymes all over the world in innovative product formats
that facilitate development and quality control of biological drugs.

The Group consists of Genovis AB and the wholly owned subsidiary Genovis Inc.
(USA).

Genovis shares are listed on Nasdaq Stockholm First North, and Consensus is
Certified Adviser for the Company, t: 46 (0)31-745 50 00

This press release is a translation of the Swedish original. In the event of any
discrepancy between this translation and the Swedish original,
the Swedish version shall prevail.

Attachments

09256199.pdf